Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
Live Interviews Editor's pick

Onyx @ Jefferies: Warner Biddle, CEO, Kyverna Therapeutics

Fresh momentum from Jefferies and a new $150 million non-dilutive financing has extended its runway into 2027.

Dr. Adil Ali
Published
1 min read

📈 Stock

Kyverna Therapeutics
NASDAQ: KYTX
Data and chart by TradingView.

Kyverna Therapeutics is emerging as one of the most closely watched players in autoimmune cell therapy.

Their CD19 CAR-T program KYV-101 is advancing toward registrational studies in stiff person syndrome and myasthenia gravis.

Please sign-up to continue reading

Subscribe

Be the first to receive exclusive interviews with cutting-edge biotech and pharma CEOs, straight to your inbox. Unsubscribe at any time. Already have an account? Sign In

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

More Live Interviews ↗